Stock Events

Stock Events

Pulmatrix 

$1.38
29
+$0.02+1.47% Today

Statistics

Day High
1.4
Day Low
1.35
52W High
9.09
52W Low
1.19
Volume
128,263
Avg. Volume
-
Mkt Cap
5.04M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

8MayExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-1.59
-1.14
-0.69
-0.24
Expected EPS
N/A
Actual EPS
N/A

Financials

-122.46%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
15.61MRevenue
-19.12MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PULM. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals focuses on developing inhalation therapies for cystic fibrosis, directly competing with Pulmatrix's respiratory disease treatments.
GSK
GSK
Mkt Cap103.01B
GlaxoSmithKline produces a range of respiratory products, including treatments for asthma and COPD, competing in the same market as Pulmatrix.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca has a strong portfolio in respiratory care, including treatments for asthma and COPD, making it a direct competitor to Pulmatrix.
Insmed
INSM
Mkt Cap28.76B
Insmed Incorporated specializes in rare lung diseases, offering products that compete with Pulmatrix's treatments for respiratory disorders.
Champion Industries
CHMP
Mkt Cap1,129
ChampionX Corporation, though not a direct pharmaceutical competitor, provides technologies and solutions that could indirectly compete with Pulmatrix's drug delivery technologies.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.7B
Teva Pharmaceutical Industries has a broad portfolio that includes respiratory treatments, competing with Pulmatrix in the generic and specialty medicine sectors.
Novartis
NVS
Mkt Cap279.67B
Novartis offers a wide range of healthcare products, including treatments for respiratory conditions, making it a competitor in the broader healthcare market.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. develops medications for various conditions, including respiratory diseases, positioning it as a competitor in the pharmaceutical industry.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a diverse portfolio of health care products, including treatments for respiratory conditions, competing across multiple segments with Pulmatrix.
Biogen
BIIB
Mkt Cap27.62B
Biogen focuses on advanced therapies for serious diseases, including respiratory conditions, indirectly competing with Pulmatrix in the biopharmaceutical sector.

About

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Show more...
CEO
Mr. Peter Ludlum CMA, MBA
Employees
2
Country
United States
ISIN
US74584P3010

Listings

MU
DE
2PU.MU
STU
DE
2PU.STU
F
DE
2PU.F
XNAS
US
PULM

0 Comments

Share your thoughts

FAQ

What is Pulmatrix stock price today?▼
The current price of PULM is $1.38 USD — it has increased by +1.47% in the past 24 hours. Watch Pulmatrix stock price performance more closely on the chart.
What is Pulmatrix stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Pulmatrix stocks are traded under the ticker PULM.
Is Pulmatrix stock price growing?▼
PULM stock has risen by +11.29% compared to the previous week, the month change is a +4.55% rise, over the last year Pulmatrix has showed a -77.9% decrease.
What is Pulmatrix market cap?▼
Today Pulmatrix has the market capitalization of 5.04M
When is the next Pulmatrix earnings date?▼
Pulmatrix is going to release the next earnings report on May 08, 2026.
What were Pulmatrix earnings last quarter?▼
PULM earnings for the last quarter are -0.24 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Pulmatrix revenue for the last year?▼
Pulmatrix revenue for the last year amounts to 15.61M USD.
What is Pulmatrix net income for the last year?▼
PULM net income for the last year is -19.12M USD.
How many employees does Pulmatrix have?▼
As of May 06, 2026, the company has 2 employees.
In which sector is Pulmatrix located?▼
Pulmatrix operates in the Health & Wellness sector.
When did Pulmatrix complete a stock split?▼
The last stock split for Pulmatrix was on March 01, 2022 with a ratio of 1:20.
Where is Pulmatrix headquartered?▼
Pulmatrix is headquartered in Framingham, United States.